Royal Philips (NYSE:PHG) announced today that it launched its Tempus ALS remote monitoring and defibrillator system for pre-hospital settings.

Amsterdam-based Philips’ end-to-end system combining hardware and software to expand the pre-hospital scope for first responders received FDA 510(k) clearance and is now on the market in the U.S., the company said in a news release.

Tempus ALS includes a remote portable vital signs patient monitor (Tempus Pro) and a remote professional defibrilator (Tempus LS-Manual) that can be used separately, too. Additionally, the devices connect wirelessly to share data and transfer vitals, waveforms and images into Philips’ IntelliSpace Corsium software platform.

“In emergency situations, where seconds count, having access to advanced patient data collection and sharing and real-time secure data streaming, can help inform confident treatment and transport decisions outside the hospital,” Philips therapeutic care GM Arman Voskerchyan said in the release. “The integrated remote monitoring and defibrillator solution combined with our web-based software platform will help front line responders provide emergency care, diagnosis and treatment – including defibrillation therapy, data management and clinical and operational efficiency features – in a fully integrated solution.”